Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290193 · ClinicalTrials.gov registry record · Phase 2
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
A Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 7
- Study locations
NCT06290193 is a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 86 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT06290193, a Phase 2 study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 7
- Study locations
Study Summary
Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution/ANH may decrease the need for allogenic blood transfusion/ABT in people having primary cytoreductive surgery.
Conditions Studied
Interventions
- BIOLOGICAL Acute Normovolemic Hemodilution/ANH
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities) - Commack
- Memorial Sloan Kettering Westchester (Limited protocol activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2024-02-23 |
| Est. Completion | 2029-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06290193
The ClinicalTrials.gov registry entry for NCT06290193 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Acute Normovolemic Hemodilution/ANH is the first listed.
NCT06290193 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06290193 about?
NCT06290193 is a clinical study titled "Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery". Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard sur...
What is the current status of trial NCT06290193?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2024-02-23. Estimated completion is 2029-02-23.
What conditions does trial NCT06290193 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Ovarian Carcinoma, Peritoneal Cancer, Fallopian Tube Carcinoma.
What interventions are being tested in trial NCT06290193?
The interventions under investigation include: Acute Normovolemic Hemodilution/ANH (BIOLOGICAL).
Who is sponsoring clinical trial NCT06290193?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290193 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.